| Today's News and Trends | AI has already made a massive impact on healthcare, especially in the fields of cardiology and radiology. With the FDA clearing more and more algorithms, this trend is only expected to grow as time goes on. AI has already made a massive impact on healthcare, especially in the fields of cardiology and radiology. With the FDA clearing more and more algorithms, this trend is only expected to grow as time goes on. | | |
| Dave Dixon, PharmD, explored the short- and long-term impact of these approvals, noting that they could help reduce costs down the line. Dave Dixon, PharmD, explored the short- and long-term impact of these approvals, noting that they could help reduce costs down the line. | | |
| Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access. Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access. | | |
| | The new document represents the ACC’s first Concise Clinical Guidance; it was designed to be an easy-to-use reference for keeping track of a complicated topic. The new document represents the ACC’s first Concise Clinical Guidance; it was designed to be an easy-to-use reference for keeping track of a complicated topic. | | |
| Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients. Howard Herrmann, MD, MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients. | | |
| “Clear signs of an aortic dissection” were missed in the patient's imaging findings after he presented to the emergency room, according to the lawsuit. He was diagnosed with acute pericarditis at the time and sent home—and then died four days later. “Clear signs of an aortic dissection” were missed in the patient's imaging findings after he presented to the emergency room, according to the lawsuit. He was diagnosed with acute pericarditis at the time and sent home—and then died four days later. | | |
| Researchers explored five-year data from more than 1,800 patients with nonvalvular AFib who underwent LAAO with Abbott's Amulet or Boston Scientific's Watchman 2.5. Researchers explored five-year data from more than 1,800 patients with nonvalvular AFib who underwent LAAO with Abbott's Amulet or Boston Scientific's Watchman 2.5. | | |
| | The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients. The biggest differences, researchers noted, were found in the long-term outcomes of low- and intermediate-risk patients. | | |
| Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI. Evan Shlofmitz, DO, director of intravascular imaging at St. Francis Hospital, explains how advanced artificial intelligence technology is used to assess a patient's CT scan before they undergo PCI. | | |
| Pi-Cardia, an Israeli medtech company, describes ShortCut as the “world’s first dedicated leaflet modification device." Pi-Cardia, an Israeli medtech company, describes ShortCut as the “world’s first dedicated leaflet modification device." | | |
| | As the use of AI in imaging continues to grow, it’s “become clear" that real world performance of these products can defer from premarket testing, experts note. As the use of AI in imaging continues to grow, it’s “become clear" that real world performance of these products can defer from premarket testing, experts note. | | |
| The incident cost the clinic tens of thousands of dollars in repairs. The incident cost the clinic tens of thousands of dollars in repairs. | | |
| |
|
| ![]() | |
|
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](https://cardiovascularbusiness.com/sites/default/files/styles/media_thumbnail/public/2024-09/istock-1209664264.jpg?itok=d9hdApI9)
